Mostrar el registro sencillo del ítem
Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus
dc.rights.license | open | en_US |
dc.contributor.author | CHALOUNI, Mathieu | |
dc.contributor.author | VAN SANTEN, Daniela K | |
dc.contributor.author | BERENGUER, Juan | |
dc.contributor.author | JARRIN, Inmaculada | |
dc.contributor.author | MIRO, Jose M | |
dc.contributor.author | KLEIN, Marina B | |
dc.contributor.author | YOUNG, Jim | |
dc.contributor.author | TORGERSEN, Jessie | |
dc.contributor.author | RENTSCH, Christopher T | |
dc.contributor.author | GILL, M John | |
dc.contributor.author | EPSTEIN, Rachel L | |
dc.contributor.author | LINAS, Benjamin | |
dc.contributor.author | ZANGERLE, Robert | |
dc.contributor.author | SURIAL, Bernard | |
dc.contributor.author | RAUCH, Andri | |
dc.contributor.author | TOULOUMI, Giota | |
dc.contributor.author | PAPADOPOULOS, Antonios | |
hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | WITTKOP, Linda | |
dc.contributor.author | VAN DER VALK, Marc | |
dc.contributor.author | BOYD, Anders | |
dc.contributor.author | MONFORTE, Antonella D'Arminio | |
dc.contributor.author | PUOTI, Massimo | |
dc.contributor.author | LOGAN, Roger W | |
dc.contributor.author | REIN, Sophia M | |
dc.contributor.author | HERNAN, Miguel A | |
dc.contributor.author | LODI, Sara | |
dc.date.accessioned | 2025-04-10T15:39:12Z | |
dc.date.available | 2025-04-10T15:39:12Z | |
dc.date.issued | 2025-02-19 | |
dc.identifier.issn | 1473-5571 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/206104 | |
dc.description.abstractEn | OBJECTIVE: People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events and HCV transmission to others. DESIGN: Target trial emulation with observational data collected in routine clinical practice from a collaboration of cohorts from Europe and North America. METHODS: We included DAA-naïve adults with HIV-HCV co-infection who achieved HIV virologic suppression (HIV RNA<50 copies/mL) after starting ART between 2013-2020. We 1) estimated the probability of not initiating DAAs at 6 and 36 months after HIV virologic suppression, and 2) emulated a target trial of early (≤6 months after HIV virological suppression) versus delayed (>6 months) DAA initiation and the 36-month risk of liver-related events (liver decompensation or hepatocellular carcinoma). RESULTS: Of 862 eligible individuals (median age 46 years; interquartile range 36 to 56), 14% were women, and 52% had a history of injection drug use. The 6 and 36-month probabilities of not initiating DAA were 58% (95% CI: 55, 61) and 24% (21, 27), respectively. The 36-month risk of liver-related events was 1.1% (0.4, 2.0) for early initiation and 1.7% (0.7, 2.5) for delayed initiation; risk difference -0.5% (-1.2, 0.4). CONCLUSIONS: Almost one-quarter of people with HIV-HCV co-infection on ART had not initiated DAA 3 years after HIV virologic suppression. Because the 3-year risk of liver-related events was low, estimates of the impact of delayed DAA initiation were imprecise. | |
dc.language.iso | EN | en_US |
dc.title.en | Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus | |
dc.title.alternative | AIDS | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1097/qad.0000000000004161 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 39970192 | en_US |
bordeaux.journal | AIDS. Official journal of the international AIDS Society | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.institution | INRIA | |
bordeaux.team | SISTM_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-05029812 | |
hal.version | 1 | |
hal.date.transferred | 2025-04-10T16:02:02Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=AIDS.%20Official%20journal%20of%20the%20international%20AIDS%20Society&rft.date=2025-02-19&rft.eissn=1473-5571&rft.issn=1473-5571&rft.au=CHALOUNI,%20Mathieu&VAN%20SANTEN,%20Daniela%20K&BERENGUER,%20Juan&JARRIN,%20Inmaculada&MIRO,%20Jose%20M&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |